Peptide Receptor Radionuclide Therapy in Patients with Somatostatin Receptor‐Positive Neuroendocrine Tumors

Essen, Marc van; Kwekkeboom, Dik J.; Herder, Wouter W. de; Bodei, Lisa; Kam, Boen L.R.; Jong, Marion de; Valkema, Roelf; Krenning, Eric P.

doi:10.1002/9780470613214.ch4

Cited by 3 publications

(2 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…although this find ing has been shown previously in smaller studies 2 and is known among ne uroendocrine tumor specialists, this new, large study should convince more health-care providers of the efficacy of 90 Y-edoctreotide for the treatment of metastatic carcinoids.…”

mentioning

confidence: 77%

Radioactive somatostatin analog therapy against carcinoids

2010

Nat Rev Endocrinol

View full text Add to dashboard Cite

mentioning

confidence: 77%

Radioactive somatostatin analog therapy against carcinoids

2010

Nat Rev Endocrinol

View full text Add to dashboard Cite

“…However, in the last few years, 177 Lu [E max,b = 498 keV (78.6%); energy of g emissions (E g = 113 and 210 keV, 6.4% and 11%, respectively); T 1/2 phys = 6.73 days and R max = 2 mm] [5] has been increasingly substituting 90 Y owing to the shorter penetration range in tissue of its electrons and the lower renal absorbed dose (a kidney-to-kidney dose factor of 4.88 Â 10 -4 for 90 Y versus 8 Â 10 -5 for 177 Lu] [6]. Moreover, the contemporary b and g emission of 177 Lu makes it suitable both for therapeutic and diagnostic purposes [7].…”

Section: Introductionmentioning

confidence: 97%

Personnel exposure in labelling and administration of 177Lu-DOTA-D-Phe1-Tyr3-octreotide

Sghedoni¹,

Grassi²,

Fioroni³

et al. 2011

Nuclear Medicine Communications

View full text Add to dashboard Cite

In this study, an evaluation of the skin equivalent doses during (177)Lu-DOTATOC labelling and administration is presented. These data can be useful to assess the risk for workers in centres that are starting to implement PRRT using (177)Lu. The use of appropriate protection devices and procedures allows the observance of International Commission for Radiological Protection dose limits for exposed workers.

show abstract

Vectors for the Delivery of Radiopharmaceuticals in Cancer Therapeutics

Chaturvedi

Mishra

2014

Ther. Deliv.

View full text Add to dashboard Cite

Internal radiation using radiopharmaceuticals promises efficient cancer therapeutics. The specificity and selectivity required for screening and pinpointing tumor cells for cell-kill has been made possible by targeted ligands based on 'magic bullet' and tracer principle- theories nearing a century. Overexpression of certain receptors has been exploited using biomolecules for targeting. The pragmatic analysis, however, is not as promising compared with the theoretical knowledge of available gamut of vectors and targets. The complex interplay of in vitro and in vivo parameters, and the effect of radionuclides involve a systematic assessment of radiopharmaceuticals as diagnostic and therapeutic agent. This review presents different vectors with their pros and cons, present status and recent design variations followed by a future perspective based on novel approaches.

show abstract

Peptide Receptor Radionuclide Therapy in Patients with Somatostatin Receptor‐Positive Neuroendocrine Tumors

Cited by 3 publications

References 59 publications

Radioactive somatostatin analog therapy against carcinoids

Radioactive somatostatin analog therapy against carcinoids

Personnel exposure in labelling and administration of 177Lu-DOTA-D-Phe1-Tyr3-octreotide

Vectors for the Delivery of Radiopharmaceuticals in Cancer Therapeutics

Contact Info

Product

Resources

About